| Número de catálogo | HF879026 |
|---|
| Reactividad de especies | Human |
|---|
| Aplicaciones | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
|---|
| Especie huésped | Human |
|---|
| Clonalidad | Monoclonal |
|---|
| Isotipo | IgG1, kappa |
|---|
| Actividad biológica |
Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2]. The elimination half-life (t 1/2) of Adalimumab is long (~20 days) [1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2]. |
| Aplicaciones probadas |
FCM |
| Objetivo |
C-domain 1, C-domain 2, Cachectin, ICD1, ICD2, Intracellular domain 1, Intracellular domain 2, N-terminal fragment, NTF, TNF, TNF-a, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor, Tumor necrosis factor ligand superfamily member 2, Tumor necrosis factor, membrane form, Tumor necrosis factor, soluble form |
| Nivel de endotoxinas |
< 10 EU/mg |
| Pureza |
>95% as determined by SDS-PAGE. |
| Purificación |
Protein A/G purified from cell culture supernatant. |
| Número de acceso |
P01375 |
| Forma |
Liquid |
| Buffer de almacenamiento |
0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
|
| Estabilidad y almacenamiento |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | ABP501, D2E7, Adalimumab, AdalimumabBeta, 331731-18-1 |
|---|
| Fondo | Tumor necrosis factor (TNFa/TNF-alpha) is a ~25 kDa protein. Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective. TNFa is the therapeutic target of adalimumab (Humira). 2. Friedmann, E. et al. (2006) Nature cell biology 8, 843-8. PMID: 168299523. Jinesh G, G. et al. (2012) Journal of leukocyte biology 92, 233-44. PMID: 225179184. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 12794819 |
|---|
| Referencias |
1. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [HF879026]
2. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. [HF879026] |
| Nota |
For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control |
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
中文
English
한국어
日本語
Español
Français
Русский
